- Home
- BMY
as 06-30-2025 3:30pm EST
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
| Founded: | 1887 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 97.6B | IPO Year: | N/A |
| Target Price: | $58.33 | AVG Volume (30 days): | 13.5M |
| Analyst Decision: | Hold | Number of Analysts: | 16 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 2.67 | EPS Growth: | N/A |
| 52 Week Low/High: | $39.35 - $63.33 | Next Earning Date: | 07-31-2025 |
| Revenue: | $47,636,000,000 | Revenue Growth: | 4.62% |
| Revenue Growth (this year): | -3.33% | Revenue Growth (next year): | -7.01% |
Latest Bristol-Myers Squibb Company News
BMY Breaking Stock News: Dive into BMY Ticker-Specific Updates for Smart Investing
Insider Monkey
11 hours ago
Jim Cramer Highlights That Incyte’s New CEO is an “Industry Veteran”
Pharmaceutical Technology
3 days ago
FDA approves label updates for BMS’ CAR T cell therapies
MT Newswires
4 days ago
Bristol-Myers Squibb Gets FDA Approval to Streamline Patient Monitoring, Risk Mitigation for Cancer Therapies
GlobeNewswire
4 days ago
Sickle Cell Disease Treatment Market Analysis and Forecast, 2025-2035 | Intensifying Competition as Key Players Advance Gene and Novel Therapies
Business Wire
4 days ago
U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels
Investor's Business Daily
4 days ago
Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role?
Zacks
4 days ago
Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?
Investor's Business Daily
4 days ago
Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes
Compare BMY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BMY Bristol-Myers Squibb Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.